KryZ
2021-06-30
Biotechs are risky plays but can hit jackpot if lucky!
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":153580751,"tweetId":"153580751","gmtCreate":1625034591673,"gmtModify":1631887569725,"author":{"id":3574671514316116,"idStr":"3574671514316116","authorId":3574671514316116,"authorIdStr":"3574671514316116","name":"KryZ","avatar":"https://static.tigerbbs.com/91c62b44c75f8a4a9e0b7566bd02134d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":38,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Biotechs are risky plays but can hit jackpot if lucky!</p></body></html>","htmlText":"<html><head></head><body><p>Biotechs are risky plays but can hit jackpot if lucky!</p></body></html>","text":"Biotechs are risky plays but can hit jackpot if lucky!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/153580751","repostId":1100317118,"repostType":4,"repost":{"id":"1100317118","kind":"news","pubTimestamp":1625030487,"share":"https://www.laohu8.com/m/news/1100317118?lang=zh_CN&edition=full","pubTime":"2021-06-30 13:21","market":"us","language":"en","title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","media":"Motley Fool","summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","content":"<p>The <b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>The<b>纳斯达克复合材料</b>（NASDAQINDEX：^IXIC）最近表现良好，创下历史新高。该指数周二保持势头，截至美国东部时间中午12:30上涨略高于0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in <b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新型公司而闻名，周二几只生物科技股受到了广泛关注。<b>Cerevel治疗控股公司</b>（纳斯达克：CERE）股价上涨，但投资者<b>唤醒生物治疗</b>（纳斯达克：SNSE）就没那么幸运了。下面，您将获得这两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel的股价在盘中早些时候上涨了一倍多后，周二中午上涨了95%。这家生物技术公司从其关键候选治疗方法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其治疗精神分裂症CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的通用评分系统中产生了具有统计学意义的改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel的首席科学官认为，这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免该疾病其他类型治疗方法的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>不到一年前，Cerevel通过SPAC与Arya Sciences Acquisition合并上市。由于该股远高于此后的任何交易价格，Cerevel现在牢牢地受到了整个市场生物技术投资者的关注。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics的股价则相反，下跌超过15%。投资者对这家免疫治疗专家对其治疗管道进行战略重新优先排序的消息并不高兴。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei决定将重点转移到当前的候选产品上，其中包括免疫噬菌体治疗SNS-401-NG和单克隆抗体SNS-VISTA。通过这样做，它希望扩大可用现金以支付2024年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着唤醒将不再继续其SNS-301计划。在分析了单抗原治疗的临床活动和特定数据后，Sensei相信它已经从第一代候选药物中获得了尽可能多的见解。唤醒的进一步行动应该很快就会到来，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年得到进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei刚刚在2月初通过IPO上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei以每股19美元的价格向IPO投资者出售了700万股股票。首日的兴奋使该股高达每股26.50美元，但事实证明这些涨幅是短暂的，此后该股稳步走低。现在它的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时会产生巨大的收益，当事情进展不顺利时会产生巨大的损失。今天的消息传出后，Sensei的未来似乎比以前更加令人怀疑，但投资者正在仔细研究Cerevel从长远来看可能提供的服务。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-30 13:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The <b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>The<b>纳斯达克复合材料</b>（NASDAQINDEX：^IXIC）最近表现良好，创下历史新高。该指数周二保持势头，截至美国东部时间中午12:30上涨略高于0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in <b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新型公司而闻名，周二几只生物科技股受到了广泛关注。<b>Cerevel治疗控股公司</b>（纳斯达克：CERE）股价上涨，但投资者<b>唤醒生物治疗</b>（纳斯达克：SNSE）就没那么幸运了。下面，您将获得这两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel的股价在盘中早些时候上涨了一倍多后，周二中午上涨了95%。这家生物技术公司从其关键候选治疗方法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其治疗精神分裂症CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的通用评分系统中产生了具有统计学意义的改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel的首席科学官认为，这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免该疾病其他类型治疗方法的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>不到一年前，Cerevel通过SPAC与Arya Sciences Acquisition合并上市。由于该股远高于此后的任何交易价格，Cerevel现在牢牢地受到了整个市场生物技术投资者的关注。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics的股价则相反，下跌超过15%。投资者对这家免疫治疗专家对其治疗管道进行战略重新优先排序的消息并不高兴。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei决定将重点转移到当前的候选产品上，其中包括免疫噬菌体治疗SNS-401-NG和单克隆抗体SNS-VISTA。通过这样做，它希望扩大可用现金以支付2024年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着唤醒将不再继续其SNS-301计划。在分析了单抗原治疗的临床活动和特定数据后，Sensei相信它已经从第一代候选药物中获得了尽可能多的见解。唤醒的进一步行动应该很快就会到来，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年得到进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei刚刚在2月初通过IPO上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei以每股19美元的价格向IPO投资者出售了700万股股票。首日的兴奋使该股高达每股26.50美元，但事实证明这些涨幅是短暂的，此后该股稳步走低。现在它的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时会产生巨大的收益，当事情进展不顺利时会产生巨大的损失。今天的消息传出后，Sensei的未来似乎比以前更加令人怀疑，但投资者正在仔细研究Cerevel从长远来看可能提供的服务。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CERE":"Cerevel Therapeutics Holdings, Inc.","SNSE":"Sensei Biotherapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317118","content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","news_type":1,"symbols_score_info":{"SNSE":0.9,"CERE":0.9}},"isVote":1,"tweetType":1,"viewCount":514,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":45,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/153580751"}
精彩评论